



# CLINICAL REPORT GUIDE

The OVA1® report helps you get a better assessment of cancer risk when managing pelvic masses.

**OVA1® Score**  
OVA1® score can be viewed here.

**ASPIRA LABS®**

<b>Patient Info</b> Last Name: XXXXXXXXXXXXXXXXXXXX First Name: MRN: DOB: Age: Gender: Ethnicity:	<b>Provider Info</b> Ordering Provider: Practice Name Street Address City, State, Zip Tel: Fax: Copy-to-Physician: Fax:	<b>Laboratory Info</b> Accession No: Client No: Collection Date: Received Date: Final Report Date:
--	---	---

**Clinical Information:** ? Ultrasound Results Unknown      **Menopausal Status:**  Premenopausal

Test Name	Result	Status	Reference Range
<b>Ova1</b>	<b>3.0</b>	<b>Low Risk</b>	<b>Premenopausal</b> Low Risk < 5.0 Elevated Risk ≥ 5.0

**Interpretation:**  
A **LOW RISK OVA1** results in a Risk of Malignancy of 1%, or 2% when combined with ultrasound results (see below). Results should be interpreted along with clinical and ultrasound assessment. A low risk value has been determined to have a negative predictive value of 98%.

*Providing Menopausal status and Ultrasound results helps to narrow down the risk of Malignancy*

**Risk of Malignancy: 2%** (premenopausal, **low risk** ultrasound)  
or  
**Risk of Malignancy: 3%** (premenopausal, **high risk** ultrasound)

\*Risk of Malignancy is a combination of the OVA1 Result, Menopausal status and Ultrasound results

Test Name	Result	Status	Reference Range
<b>Epithelial Tumor Markers</b>			
CA-125 II <sup>1</sup>	<b>10.0 U/mL</b>	<b>Normal Range</b>	<b>Premenopausal</b> ≤ 63.0 U/mL
<b>Epithelial Tumor Markers (Mucinous type)</b>			
CA 19.9	15.0 U/mL	<b>Normal Range</b>	≤ 35.0 U/mL
CEA	3.0 ng/mL	<b>Normal Range</b>	Non Smokers < 5.0 ng/mL Smokers < 6.5 ng/mL

**Interpretation:** Results in the normal range may suggest low risk for ovarian cancer. Epithelial-Cell Tumors make up an average of 75% of all ovarian cancer tumor types, including serous, mucinous, endometrioid, clear cell, and Brenner tumors.

---

www.aspirawh.com      aspirasupport@aspirawh.com      CLIA Lab No: 45D2073394      Page 1 of 2  
12117 Bee Caves Road Building III, Ste 100      P 1-844-ASPIRA1      NYSDOH: 8885      PRC000XXXXX  
Austin, Texas 78738      F 1-866-283-3634      Herbert Fritsche, Ph.D.      © 2020, ASPIRA Labs  
Laboratory Director

**CA-125**  
CA-125 is included in the panel of biomarkers and will be included on the results report.

**Additional Biomarkers**  
Additional Biomarkers, if ordered, will be reported here with a personalized interpretation.

**Risk of Malignancy**  
This percentage combines the OVA1® score, menopausal status, and ultrasound results. This calculation is personalized for each patient.

p: 844.277.4721 | e: aspirasupport@aspirawh.com

© 2020 ASPIRA Women's Health. All rights reserved. The ASPIRA LABS®, OVA1® and OVERA® logos are registered trademarks of ASPIRA Women's Health in the U.S. and other countries. ASPIRA Women's Health reserves the right to change this document at any time without notice and disclaims liability for editorial, pictorial or typographical errors.

